Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of metabolic profiles on the safety of drug therapy in routine care in Germany: protocol of the cohort study EMPAR.

BMJ open - 27 Apr 2020

Huebner Tatjana, Steffens Michael, Linder Roland, Fracowiak Jochen, Langner Daria, Garling Marco, Falkenberg Felix, Roethlein Christoph, Gomm Willy, Haenisch Britta, Stingl Julia

Abstract excerpt

INTRODUCTION: Pre-emptive testing of pharmacogenetically relevant single-nucleotide polymorphisms can be an effective tool in the prevention of adverse drug reactions and therapy resistance. However, most of the tests are not used as standard in routine care in Germany because of lacking evidence for the clinical and economical benefit and their impact on the usage of healthcare services. We address this issue by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Drug-Related Side Effects and Adverse Reactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germany

Share to Health Services Needs and Demand

Share to Hypolipidemic Agents

Share to Insurance, Health

Share to Machine Learning

Share to Metabolome

Source

Open in PubMed Open full text

Identifiers

PMID: 32345696
DOI: 10.1136/bmjopen-2019-032624
PMCID: PMC7213853

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of metabolic profiles on the safety of drug therapy in routine care in Germany: protocol of the cohort study EMPAR.PMID 32345696Read ↗

Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenes.Semantic proximity Read ↗

Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice.Semantic proximity Read ↗

Use of Pharmacogenetic Drugs by the Dutch PopulationSemantic proximity Read ↗

Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data.Semantic proximity Read ↗

The Value of Clinical Pharmacogenomic Guidelines That Recommend Standard of Care Over Genotype-Based Prescribing.Semantic proximity Read ↗

Impact of Pharmacogenomics in Clinical PracticeSemantic proximity Read ↗

Role of pharmacogenetics in public health and clinical health care: a SWOT analysisSemantic proximity Read ↗

Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx GuidelinesSemantic proximity Read ↗

Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?Semantic proximity Read ↗

Clinical implementation of preemptive pharmacogenomics in psychiatry: Τhe "PREPARE" study.Semantic proximity Read ↗

Pharmacogenetic Testing: Time for Clinical Practice GuidelinesSemantic proximity Read ↗

The Importance of Gene-Drug-Drug-Interactions in Pharmacogenomics Decision Support: An Analysis Based on Austrian Claims Data.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.